Vascepa (icosapent ethyl)

Vascepa (icosapent ethyl) for sale – Buy Vascepa (icosapent ethyl) online

What is Vascepa (icosapent ethyl) for?

Vascepa (icosapent ethyl) is an ethyl ester of eicosapentaenoic acid (EPA) indicated as an adjunct therapy for adult patients with:

• elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or, diabetes mellitus and two or more additional risk factors for cardiovascular disease as an adjunct to maximally tolerated statin therapy.
• severe (≥ 500 mg/dL) hypertriglyceridemia as an adjunct to diet.

Where has Vascepa (icosapent ethyl) been approved?

Vascepa (icosapent ethyl) has been approved by:

• Food and Drug Administration (FDA), USA:
  • On July 27, 2012 to reduce triglyceride levels in adults with severe hypertriglyceridemia
  • On December 13, 2019 to reduce cardiovascular risk
• Health Canada on January 2, 2020 to reduce cardiovascular risk
• European Medicines Agency (EMA) on January 29, 2021 under the brand name Vazkepa to reduce cardiovascular risk